Gland Pharma Limited (BOM: 543245)

Market Cap	276.24B
Revenue (ttm)	58.90B
Net Income (ttm)	6.92B
Shares Out	n/a
EPS (ttm)	41.98
PE Ratio	39.94
Forward PE	n/a
Dividend	20.00 (1.19%)
Ex-Dividend Date	Aug 16, 2024

Volume	3,375
Average Volume	14,428
Open	1,705.35
Previous Close	1,678.95
Day's Range	1,668.00 - 1,708.55
52-Week Range	1,590.00 - 2,220.95
Beta	n/a
RSI	35.93
Earnings Date	Feb 3, 2025

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood ...

• Industry: Pharmaceutical Preparations
• Founded: 1978
• Employees: 4,217
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543245

Financial Performance

In 2023, Gland Pharma's revenue was 56.65 billion, an increase of 56.29% compared to the previous year's 36.25 billion. Earnings were 7.72 billion, a decrease of -1.10%.